Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667901 · ClinicalTrials.gov registry record · Phase 1
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
A Phase 1 study, sponsored by University of Medicine and Dentistry of New Jersey.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00667901 is a Phase 1 study that was terminated before completion, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 15 participants.
The verdict
NCT00667901, a Phase 1 study, was terminated before completion, sponsored by University of Medicine and Dentistry of New Jersey.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.
Interventions
- GENETIC protein expression analysis
- OTHER immunohistochemistry staining method
- GENETIC western blotting
- GENETIC reverse transcriptase-polymerase chain reaction
- DRUG riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667901
The ClinicalTrials.gov registry entry for NCT00667901 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Medicine and Dentistry of New Jersey, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00667901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667901 about?
NCT00667901 is a clinical study titled "Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery". RATIONALE: Riluzole may stop or slow the growth of tumor cells and may be an effective treatment for melanoma. PURPOSE: This early phase I trial is studying how well riluzole works in treating patients with stage III or stage IV melanoma that can be removed by surgery.
What is the current status of trial NCT00667901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00667901?
The interventions under investigation include: protein expression analysis (GENETIC), immunohistochemistry staining method (OTHER), western blotting (GENETIC), reverse transcriptase-polymerase chain reaction (GENETIC), riluzole (DRUG).
Who is sponsoring clinical trial NCT00667901?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.